Post-transplant lymphoproliferative disorder (PTLD) is uncommonly of T-cell origin, especially following haematopoietic stem cell transplantation (HSCT). To date, only five cases have been reported. Four of these involved paediatric patients, 1 and the remaining case reported by Yufu et al 2 was of an adult patient who underwent autologous stem cell transplantation. Thus, our case is unique, being the first case reported of adult T-cell PTLD following a full haplotype-mismatched transplantation. Usually, PTLD is associated with EBV infection, and most are B-cell-type lymphomas. In PTLD, T-lymphocyte dysfunction caused by immunosuppressive treatment allows uncontrolled proliferation of B cells bearing the Epstein-Barr virus (EBV). 3,4 PTLD is considered rare (o1%) after allogeneic HSCT, but intensive immunosuppression, such as graft Tcell depletion, may markedly increase the risk of PTLD. 1, 2, 4 The risk factors for PTLD development after allogeneic HSCT are: (1) T-cell depletion, (2) HLA-mismatching, (3) specific antilymphocyte therapy, and (4) primary immunodeficiency. 1, 4 In the case of T-cell PTLD after HSCT, the situation may differ because there are very few cases available for study. In contrast, T-cell PTLD develops in 12-14% of solid organ transplants 2 and about 38% are EBV-positive. 3 A 22-year-old patient was diagnosed with acute myelogenous leukaemia. His chromosome showed 46 XY, dup (9) . A follow-up bone marrow showed typical leukaemic blasts of around 5%. He underwent allogeneic HSCT from his full haplotype-mismatched brother. Conditioning used was with fractionated total body irradiation 1200 cGy for chimerism. An CMV antigenaemia assay on D þ 12 was positive, and so ganciclovir 10 mg/kg/day i.v. was started. He was discharged well on D þ 31. He received further prophylactic human CMV-specific immunoglobulin (Megalotect R , Biotest Pharma, Germany) 50 U/kg/week i.v. and was closely monitored by CMV antigenaemia assay. On D þ 89, a significant level of CMV antigenaemia was again reported so he received foscarnet (Foscavir R , Astra Pharmaceuticals, USA) 100 mg/kg/day at a day care centre. CMV follow-up showed negative on two consecutive occasions and was stopped at D þ 112. However, he was admitted because of neck swelling on D þ 114. Multiple lymph node (LN) enlargement in both carotid spaces and diffuse soft tissue oedema were noted on magnetic resonance imaging. An LN biopsy revealed malignant lymphoma of the diffuse, large, T-cell type with TCR-gd positivity (Figure 1a and b) . Immunohistochemical studies were consistent with a T-cell origin (Table 1 ). In addition, EBV in situ hybridization result was positive. EBV serology findings at the time of PTLD were EBV-VCA (viral capsid antigen)-IgG positive (1:160) and VCA IgA, IgM negative. EBV EA-DR (Early antigen diffuse and restictive) IgG was weakly positive and EA-DR IgA, IgM were negative. EBV EBNA (Epstein-Barr nuclear antigen) was positive. Similar EBV status of donor and recipient had been reported pretransplant, suggesting that the EBV infection was not primary but chronic, and that the T-cell lymphoma had originated from EBV-infected T-cells that had proliferated during the latent period, probably due to the severe immunosuppressive therapy. In addition, it is likely that the origin of T-cell PTLD was probably from the donor T cells because of the stable donor chimerism confirmed by RQ-PCR. The patient died 11 days after the diagnosis of PTLD (D þ 139). At that time, his haemogram was stable without transfusion support, acute GVHD and other transplant-related complications were absent, and there was no evidence of leukaemia relapse.
The precise pathogenesis of T-cell PTLD is unknown. According to a report by Tatsuya et al, 4 EBV can simultaneously infect B and T cells and can induce clonal proliferation of both lymphocyte subsets in individuals severely immunocompromised after allogeneic HSCT. Furthermore, a study in recipients of T-cell-depleted grafts suggested that an elevated EBV-DNA load was highly predictive for the development of EBV-PTLD. 5 However, we unfortunately were unable to monitor EBV-DNA levels routinely.
EBV infects B lymphocytes via CD21 and induces oncogenesis via its gene products, in particular, EBNA 2 and latent membrane protein 1. 6 This suggests that a subset of T lymphocytes may also express CD21 and become infected with EBV. 7 Alternatively, unidentified receptors may mediate the EBV infection of T lymphocytes. Studies of patients with chronic active EBV infection have revealed EBV-induced T-cell transformation. In these studies, the EBV genome has been demonstrated in both clonally proliferating T cells and in T-cell lymphoma cells. Therefore, T lymphocytes may also undergo malignant transformation following EBV infection. One more interesting point concerns the CliniMACS system, which depletes both T and B cells. In our case, the infused Bcell count was not measured directly, but many reports have revealed that the CliniMACS system adequately depletes B cells. Some have suggested that combined Tand B-cell depletion in a HLA-mismatched HSCT graft reduces the incidence of EBV-induced B-cell PTLD. 9 Thus, we cautiously suggest that aggressive lymphocyte depletion can influence the incidence of T-cell PTLD, and believe that this issue warrants further study. Evidence also suggests that cytomegalovirus (CMV) infection following transplantation may promote EBV-associated PTLD in some patients, possibly by modulating immune responses that favour tumour-cell outgrowth. 10 In our case, the CMV antigen was positive from D þ 12, and this may have been associated with PTLD development.
In summary, this case is interesting because it is a rare example of T-cell PTLD after a full haplotype-mismatched HSCT. We believe that aggressive immunosuppressive therapy in combination with active T-cell depletion were the main causes of T-cell PTLD. The issue of T-cell PTLD following haplotype-mismatched HSCT requires further study. Moreover, guidelines should be prepared that allow this kind of complication to be predicted after haplotypemismatched transplantation, and urgent consideration should be given to the active adoption of an anti-CMV-CTL or an anti-EBV-CTL therapy. Based on our experience, adoptive transfer of EBV-specific CTL would be very effective if available in patients at the high risk of developing PTLD. cellularity. Lymphoid cells were larger than normal mature lymphocytes and had irregular and prominent nuclei and pale to eosinophilic cytoplasm. Mitoses (arrow) were frequent and some histiocytes (arrowhead) were observed, (b) Southern blot analysis of T-cell receptor gamma and delta gene rearrangements in DNA extracted from lymph node biopsy tissue. This showed that the lymphoma was of T-cell origin. 
